1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
BioGaia AB Class B

BioGaia AB Class B

129.30
SEK
+5.00
(+4.02%)
3.65EPS
32.17P/E
11.88BMarket Cap
Feb 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.65
5.58
5.58
6.17
7.1
8.56
8.79
8.37
7.77
10.93
12.84
14.08
15.2
16.4
Basic EPS, GAAP
0.71
1.71
1.4
2.63
2.08
2.48
2.14
2.01
1.94
3.7
3.62
3.48
3.29
3.65
Free Cash Flow per Basic Share
0.71
1.16
1.03
1.64
2.26
1.96
1.25
2.3
2.13
2.98
3.74
3.55
2.99
2.63
Dividend per Share
2
1.4
1
1.43
1.5
1.8
1.98
0.73
0.68
2.98
2.9
6.89
6.9
10.9
Book Value per Share
3.67
3.99
4.57
4.79
5.35
5.83
5.86
17.29
18.59
19.53
20.11
17.04
12.99
10.88
Tangible Book Value per Share
3.67
3.92
4.38
4.79
5.35
5.24
5.19
16.74
16.64
17.38
18.01
15.3
11.54
9.35
Basic Weighted Avg Shares
86
86
87
87
87
87
87
89
101
101
101
101
101
101
Sales/Revenue/Turnover
316
482
483
535
615
742
768
747
785
1,104
1,297
1,423
1,538
1,659
Operating Margin (%)
25.28
39.26
35.4
36.47
38.78
37.12
32.54
32.73
30.89
30.3
34.01
28.77
29.38
27.89
Depreciation Expense
6
6
7
7
7
8
16
21
27
24
25
26
25
24
Net Income, GAAP
62
147
121
228
181
215
187
180
196
374
365
351
333
369
Effective Tax Rate (%)
23.37
23.13
22.81
18.72
22.48
22.83
22.7
21.03
22.33
16.5
22.07
21.53
21
21.36
Profit Margin (%)
19.54
30.59
25.12
42.56
29.36
28.97
24.38
24.06
25
33.86
28.18
24.7
21.63
22.26
Working Capital
257
262
288
312
343
349
328
1,555
1,625
1,632
1,679
1,404
1,020
729
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
317
345
396
415
464
508
508
1,746
1,877
1,972
2,030
1,724
1,314
1,101
Return on Invested Capital (%)
15.54
43.29
35.61
39.81
40.64
42.9
35.74
15.78
10.78
15.55
17.08
17.48
21.42
25.26
Return on Capital (%)
15.32
44.39
32.83
56.19
41.13
44.42
36.68
15.86
10.82
19.6
18.29
18.78
22.22
25.9
Return on Common Equity (%)
16.02
44.54
32.8
56.12
41.08
44.36
36.99
15.95
10.83
19.42
18.26
18.72
21.91
25.64

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
101
101
101
Market Capitalization
10,743
12,034
11,879

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,219
1,316
941
Cash, Cash Equivalents & STI
801
872
446
Accounts Receivable, Net
216
- -
- -
Inventories
167
- -
- -
Total Current Liabilities
199
266
212
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.66%
-4.67%
-23.77%
Free Cash Flow
18.54%
9.92%
-15.62%
Net Income, GAAP
15.72%
17.65%
-5.3%
Sales/Revenue/Turnover
12.81%
16.2%
8.11%
Total Cash Common Dividend
49.59%
95.75%
0.18%

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
370
384
304
365
1,423
2025
366
405
- -
441
1,538
2026
373
441
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.21
1.1
0.36
0.81
3.48
2025
0.79
0.87
- -
0.98
3.29
2026
0.78
1.02
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
6.9
- -
- -
6.89
2025
- -
6.9
- -
- -
6.9
2026
- -
4
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Theresa Agnew
Full Time Employees
242
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Kungsbroplan 3 Stockholm AB Sweden 112 27
IPO Date
Jan 1, 1998
Website
biogaia.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
BioGaia AB (publ) develops, manufactures, markets and sells probiotic products based on patented Lactobacillus reuteri strains for gut health, immune health and oral health; offers drops, chewable tablets, oral rehydration solutions, gut health tablets, bone health tablets and oral health lozenges under the BioGaia brand including Protectis (L. reuteri DSM 17938), Prodentis (DSM 17938 and ATCC PTA 5289) and Gastrus (DSM 17938 and ATCC PTA 6475); provides cultures as ingredients for infant formula, milk formula and licensee dairy products; and supplies packaging solutions through its Other segment. The company operates in Pediatrics, Adult Health and Other segments, targeting infantile colic, digestive health in children, antibiotic-associated and acute diarrhea, gingivitis, periodontal disease, general health, H. pylori infection, low bone density and irritable bowel syndrome symptoms; sells through distribution partners and own channels in over 100 countries across EMEA (Europe, Middle East, Africa), Americas (USA, Canada, South America), APAC (Asia-Pacific), Australia and New Zealand. Founded in 1990 and headquartered in Stockholm, Sweden, BioGaia conducts research with over 270 published studies and holds 600 patents on its strains. In 2024, Anatom Holding AG acquired nearly 5 million class B shares following EQT Public Value fund's exit; the company launched BioGaia Gastrus PURE ACTION, a FODMAP-friendly, double-strength probiotic capsule for sensitive stomachs; terminated its France distribution contract to shift to direct operations; and in July 2025 established subsidiary BioGaia New Sciences AB to advance microbiome research into skin health and biotics beyond core areas. In Q3 2025, net sales rose 7% to SEK 326.6 million with Pediatrics up 7% and continued APAC and Americas growth via online sales and direct markets in Australia and New Zealand.

Company News

Company News APIChatGPT

  • seekingalpha.com

    BioGaia AB (publ) (BIOGY) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    BioGaia AB (publ) (BIOGY) Q3 2025 Earnings Call Transcript